Anat Cohen-Dayag Ph.D.
Dr. Anat Cohen-Dayag is a senior biotechnology executive with nearly three decades of leadership experience spanning therapeutic discovery and development, strategic partnering, corporate financing, global operations, and R&D innovation.
Dr. Cohen-Dayag currently serves as Executive Chair of the Board of Directors at Compugen. Prior to her appointment as Executive Chair, Dr. Cohen-Dayag served for 15 years as President and Chief Executive Officer of Compugen, where she led the company’s transformation from a computational biology service provider to a clinical-stage drug discovery and development company in the field of cancer immunotherapy, forging strategic collaborations with leading global pharmaceutical companies including AstraZeneca, Bayer, Bristol Myers Squibb and Gilead. Previously, she held various executive R&D roles at Compugen, overseeing the discovery and development of programs for novel therapeutic and diagnostic applications. Before joining Compugen, Dr. Cohen-Dayag held several senior R&D positions across multiple companies in the Israeli biotech industry.
Dr. Cohen-Dayag has extensive board experience across public and private companies contributing to innovation throughout the biotech ecosystem,. In addition, she mentors emerging CEOs and actively supports the advancement of women executives into C-suite leadership positions within the life sciences sector.
Dr. Cohen-Dayag earned her B.Sc. in Biology from Ben-Gurion University, her M.Sc. in Chemical Immunology and her Ph.D. in Cellular Biology from the Weizmann Institute of Science.